Replies to post #70261 on Decision Diagnostics Corp (DECN)

[rawman]

Second sources to support or dispute the Company supplied information can be helpful!

IPwatcher Monday, 03/30/20 09:54:52 PM
Re: JEM165 Post#6551
Post #65529

I've Read it.
Let me summarize:

"~20 (Japanese, not Korean) people in a cleaned up lab using millions worth of equipment showed that a cleaned up sample of a virus caused an impedance change in a cleaned up sample of a precision manufactured electrode."
>>In 2015.

On the basis of which we are led to believe that a loss making company with no employees, no cash, but some toll manufactured test strips based on 20 year old technology that is being rapidly obsoleted, and being sold at a loss - can reliably sniff out a brand new virus in one of the most challenging sample media that exists?
>>In 2020.
3 months after they first heard of its existence.

Excuse my scepticism.
Its just that I am not THAT stupid!

That, and the fact that I have got 24 years experience in diagnostic assays, am up to date with current state of the art, and therefore KNOW that the DECN press statements are complete bovine excrement.
I would never claim to know it all.
But this DECN stuff is for the birds!


If you wanted to do an impedance assay (and you wouldn't) you would use colloidal gold as a label. And you'd still struggle to get that to work in whole blood because of the non specific protein binding.

IPwatcher Monday, 03/30/20 07:27:38 PM
Re: nonsequetor Post #65452
Post #65466

Wow!

They've designed a box.

Clever DECN. Time for a lie down! That must have REALLY taken it out of them.

Wonder when they will get round to actually developing the product?
And generating some clinical data?

I strongly suspect NEVER!

A label free impedance based affinity biosensor in a dirty medium like blood is a pretty big ask because of the non specific binding effects (massive background).

And a labelled based affinity biosensor doesn't need (or particularly want) an impedance based transduction. There is little or no point, especially when it is a binary detection. Just introduces unnecessary complexity.

So even if DECN had access to the required antigens (which I SERIOUSLY doubt), and had the first idea of what to do with them (which I also SERIOUSLY doubt!) their smbg 'impedence' platform either would not subsequently work, or best case, would offer no advantage over cheaper methodologies (Photometric based).

There are proper companies out there with real employees and successful track records, and better resources, working on this.